FMN2 is a novel regulator of the cyclin-dependent kinase inhibitor p21

Cell Cycle

Volumn 12, Issue 15, 2013, Pages 2348-2354

  Yamada, Kayo ^a   Ono, Motoharu ^a   Bensaddek, Dalila ^a   Lamond, Angus I ^a   Rocha, Sonia ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Cancer; Cell cycle; DNA damage; FMN2; Hypoxia; P14ARF; P21; P53

Indexed keywords

ALANINE; ASPARTIC ACID; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 2A; FMN2 PROTEIN; MEMBRANE PROTEIN; METHENAMINE; PROTEIN P21; THREONINE; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

ACTIN FILAMENT; ACUTE LYMPHOBLASTIC LEUKEMIA; ALTERNATIVE RNA SPLICING; AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; BRAIN CANCER; CELL CYCLE ARREST; CELL PROLIFERATION; CELLULAR DISTRIBUTION; COLORECTAL CANCER; CYTOSKELETON; DNA DAMAGE; INHIBITION KINETICS; MASS SPECTROMETRY; MELANOMA; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; PROTEIN TARGETING; TRANSCRIPTION INITIATION SITE; TRANSIENT EXPRESSION; UPREGULATION;

CANCER; CELL CYCLE; DNA DAMAGE; FMN2; HYPOXIA; P14ARF; P21; P53;

ANIMALS; CELL HYPOXIA; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA DAMAGE; GENE EXPRESSION REGULATION; HUMANS; MICROFILAMENT PROTEINS; NUCLEAR PROTEINS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOLYSIS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA;

EID: 84881501068     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.25511     Document Type: Article

References (23)

1. Ozenne P, Eymin B, Brambilla E, Gazzeri S. The ARF tumor suppressor: structure, functions and status in cancer. Int J Cancer 2010; 127:2239-47; PMID:20549699; http://dx.doi.org/10.1002/ijc.25511
2. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007; 8:275-83; PMID:17380161; http://dx.doi.org/10.1038/nrm2147
3. Yamada K, Ono M, Perkins ND, Rocha S, Lamond AI. Identification and functional characterization of FMN2, a regulator of the cyclin-dependent kinase inhibitor p21. Mol Cell 2013; 49:922-33; PMID:23375502; http://dx.doi.org/10. 1016/j. molcel.2012.12.023
4. Yu J, Zhang L. The transcriptional targets of p53 in apoptosis control. Biochem Biophys Res Commun 2005; 331:851-8; PMID:15865941; http://dx.doi. org/10.1016/j.bbrc.2005.03.189
5. Larance M, Ahmad Y, Kirkwood KJ, Ly T, Lamond AI. Global subcellular characterization of protein degradation using quantitative proteomics. Mol Cell Proteomics 2013; 12:638-50; PMID:23242552; http://dx.doi.org/10.1074/mcp.M112. 024547
6. Ahmad Y, Boisvert FM, Lundberg E, Uhlen M, Lamond AI. Systematic analysis of protein pools, isoforms, and modifications affecting turnover and subcellular localization. Mol Cell Proteomics 2012; 11:013680; PMID:22002106; http://dx.doi. org/10.1074/mcp.M111.013680
7. Boisvert FM, Ahmad Y, Gierliński M, Charrière F, Lamont D, Scott M, et al. A quantitative spatial proteomics analysis of proteome turnover in human cells. Mol Cell Proteomics 2012; 11:011429; PMID:21937730; http://dx.doi.org/10.1074/mcp. M111.011429
8. Lam YW, Lamond AI, Mann M, Andersen JS. Analysis of nucleolar protein dynamics reveals the nuclear degradation of ribosomal proteins. Curr Biol 2007; 17:749-60; PMID:17446074; http://dx.doi. org/10.1016/j.cub.2007.03.064
9. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009; 9:400-14; PMID:19440234; http://dx.doi.org/10. 1038/nrc2657
10. Romanov VS, Pospelov VA, Pospelova TV. Cyclin-dependent kinase inhibitor p21(Waf1): contemporary view on its role in senescence and oncogenesis. Biochemistry (Mosc) 2012; 77:575-84; PMID:22817456; http://dx.doi.org/10.1134/ S000629791206003X
11. Leader B, Lim H, Carabatsos MJ, Harrington A, Ecsedy J, Pellman D, et al. Formin-2, polyploidy, hypofertility and positioning of the meiotic spindle in mouse oocytes. Nat Cell Biol 2002; 4:921-8; PMID:12447394; http://dx.doi.org/10. 1038/ncb880
12. Faix J, Grosse R. Staying in shape with formins. Dev Cell 2006; 10:693-706; PMID:16740473; http://dx.doi.org/10.1016/j.devcel.2006.05.001
13. Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 2008; 26:1367-72; PMID:19029910; http://dx.doi.org/10.1038/nbt.1511
14. Cox J, Neuhauser N, Michalski A, Scheltema RA, Olsen JV, Mann M. Andromeda: a peptide search engine integrated into the MaxQuant environment. J Proteome Res 2011; 10:1794-805; PMID:21254760; http://dx.doi.org/10.1021/ pr101065j
15. Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER 3rd, Hurov KE, Luo J, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007; 316:1160-6; PMID:17525332; http://dx.doi.org/10.1126/science.1140321
16. Rocha S, Perkins ND. ARF the integrator: linking NFκB, p53 and checkpoint kinases. Cell Cycle 2005; 4:756-9; PMID:15970704; http://dx.doi. org/10.4161/cc.4.6.1739
17. Szklarczyk R, Heringa J, Pond SK, Nekrutenko A. Rapid asymmetric evolution of a dual-coding tumor suppressor INK4a/ARF locus contradicts its function. Proc Natl Acad Sci U S A 2007; 104:12807-12; PMID:17652172; http://dx.doi.org/10.1073/pnas.0703238104
18. Kim SH, Mitchell M, Fujii H, Llanos S, Peters G. Absence of p16INK4a and truncation of ARF tumor suppressors in chickens. Proc Natl Acad Sci U S A 2003; 100:211-6; PMID:12506196; http://dx.doi. org/10.1073/pnas.0135557100
19. Charfi C, Voisin V, Levros LC Jr., Edouard E, Rassart E. Gene profiling of Graffi murine leukemia virusinduced lymphoid leukemias: identification of leukemia markers and Fmn2 as a potential oncogene. Blood 2011; 117:1899-910; PMID:21135260; http://dx.doi.org/10.1182/blood-2010-10-311001
20. Rocha S, Campbell KJ, Perkins ND. p53- and Mdm2-independent repression of NFkappa B transactivation by the ARF tumor suppressor. Mol Cell 2003; 12:15-25; PMID:12887889; http://dx.doi. org/10.1016/S1097-2765(03)00223-5
21. Rocha S, Garrett MD, Campbell KJ, Schumm K, Perkins ND. Regulation of NFκB and p53 through activation of ATR and Chk1 by the ARF tumour suppressor. EMBO J 2005; 24:1157-69; PMID:15775976; http://dx.doi.org/10.1038/ sj.emboj.7600608
22. Msaki A, Sánchez AM, Koh LF, Barré B, Rocha S, Perkins ND, et al. The role of RelA (p65) threonine 505 phosphorylation in the regulation of cell growth, survival, and migration. Mol Biol Cell 2011; 22:3032-40; PMID:21737676; http://dx.doi. org/10.1091/mbc.E11-04-0280
23. Campbell KJ, Witty JM, Rocha S, Perkins ND. Cisplatin mimics ARF tumor suppressor regulation of RelA (p65) nuclear factor-kappaB transactivation. Cancer Res 2006; 66:929-35; PMID:16424027; http://dx.doi.org/10.1158/0008-5472. CAN-05-2234